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Abstract Tumor necrosis factor-K converting enzyme (TACE)
is an ADAM (a disintegrin and metalloproteinases) that
comprises an active catalytic domain and several C-terminal
domains. We compare the binding affinity and association rate
constants of the N-terminal domain form of wild-type tissue
inhibitor of metalloproteinase (TIMP-3; N-TIMP-3) and its
mutants against full-length recombinant TACE and the trun-
cated form of its catalytic domain. We show that the C-terminal
domains of TACE substantially weaken the inhibitory action of
N-TIMP-3. Further probing with hydroxamate inhibitors
indicates that both forms of TACE have similar active site
configurations. Our findings highlight the potential role of the
C-terminal domains of ADAM proteinases in influencing TIMP
interactions. + 2002 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
Tumor necrosis factor-K (TNF-K) is a key pro-in£amma-
tory cytokine produced by activated monocytes and macro-
phages as part of the self-defence machinery. Excessive levels
of TNF-K are known to be responsible for the in£ammatory
features of many debilitating diseases such as rheumatoid ar-
thritis, Alzheimer’s disease, Crohn’s disease as well as various
types of autoimmune disorders [1^5]. The precursor of the
cytokine, pro-TNF-K, is a membrane-bound trimeric molecule
of 26 kDa monomers. Upon cleavage by TNF-K converting
enzyme (TACE), the active, 17 kDa form of mature TNF-K is
released into the surrounding medium. TACE is a zinc-depen-
dent metalloproteinase belonging to the ADAM proteinase (a
disintegrin and metalloproteinases) family (ADAM-17). Apart
from the enzymatically active catalytic domain, TACE also
contains a pro-domain at its N-terminus and several domains
at its C-terminus. These C-terminal domains are commonly
referred to as the disintegrin, epidermal growth factor (EGF)-
like, crambin-like, transmembrane and cytoplasmic domains.
Although there is plenty of evidence con¢rming the important
roles of these domains in inter-cellular adhesion and fertiliza-
tion [6^9], to date, no investigation has yet studied their e¡ects
on the inhibitory action of tissue inhibitor of metallopro-
teinases (TIMP).
Amongst the four species of TIMP discovered so far, only
TIMP-3 has been shown to be capable of inhibiting TACE
[10^12]. The TIMP-3 molecule is composed of 178 amino
acids, and the N-terminal two-thirds of the polypeptide is
believed to be folded into a very distinct domain highly rem-
iniscent of the oligosaccharide/oligonucleotide-binding protein
motif [13^14]. The truncated N-terminal domain of the
TIMPs has been known to form a stable, autonomous unit
capable of inhibiting many matrix metalloproteinases
(MMPs), ADAMs and ADAM proteinases with thrombo-
spondin domains at the C-termini (ADAM-TS) [11^12,15^
17]. Previously we reported that full-length recombinant
TIMP-3 and its N-terminal domain truncate (N-TIMP-3) dis-
played comparable tightness of binding against TACE [11].
We have subsequently demonstrated that N-TIMP-3 could
be further engineered into a powerful and selective inhibitor
against the catalytic domain of TACE [12]. In this report, we
provide the ¢rst evidence that the C-terminal domains of
TACE could exert a signi¢cant impact on the inhibitory ac-
tivity of N-TIMP-3 molecule.
2. Materials and methods
2.1. TACE-cat and TACE-long
TACE-cat (also known as TACE-473) is the recombinant form of
TACE enzyme that encompasses only the catalytic domain (i.e. resi-
dues 215^473) of the enzyme polypeptide. TACE-long (TACE-651),
on the other hand, is the soluble extracellular form of TACE that
incorporates the catalytic domain as well as the disintegrin, EGF-like
and crambin-like domains at the C-terminus (i.e. residues 215^651)
[18]. Both TACE-cat and TACE-long are kind gifts from Glaxo Smith
Kline Research and Development Inc., NC, USA.
2.2. Construction, puri¢cation and refolding of wild-type and mutant
N-TIMP-3
In our previous report, we described the creation of a series of
‘tailor made’ N-TIMP-3 mutants that displayed extreme binding tight-
ness against TACE-cat [12]. In this study, we extend these mutants to
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characterize the TACE-long enzyme. Hence, the construction, refold-
ing and puri¢cation details of the mutants have been described else-
where [11^12]. In essence, N-TIMP-3 inclusion bodies expressed in
Escherichia coli were dissolved in 50 ml 6 M guanidinium-Cl (GdmCl)
in 50 mM Tris^HCl, pH 7.8, in the presence of 10 mM dithiothreitol.
Solubilized proteins were pumped slowly (0.5 ml/min) into 2 l refold-
ing bu¡er containing 1.5 M GdmCl, 50 mM Tris^HCl, pH 10, con-
taining reduced and oxidized glutathione (GSH 0.10 mM and GSSG
0.40 mM). Refolding was allowed for at least 16 h at room temper-
ature. The following day, the refolding solutions were dialyzed twice
into 30 l of 50 mM Tris^HCl, pH 7.8. Insoluble N-TIMP-3 proteins
were removed by centrifugation at 12 000 g for 30 min. Soluble active
N-TIMP-3 were extracted with 50 ml Ni-NTA agarose, eluted with
0.2 M imidazole before ¢nal dialysis in 50 mM Tris^HCl, pH 7.8,
containing 25% glycerol.
2.3. Enzyme assays
The quenched £uorescent substrate, QF-45 (Mca-Ser-Pro-Leu-Ala-
Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Lys-Dnp-NH2) was used for
TACE-cat and TACE-long assays as described in our previous paper
[11,12]. A Perkin-Elmer LS-50B spectro£uorometer with thermostatic
cuvette holders was used for both kon and Ki experiments. All enzy-
matic assays were carried out at 27‡C unless otherwise stated. All
wild-type and mutant N-TIMP-3 were titrated against both TACE-
cat and gelatinase-A (MMP-2) for accurate estimation of concentra-
tion. Fluorescence assay bu¡er (10 mM CaCl2, 50 mM Tris^HCl, pH
7.5, 0.05% Brij-35, 1% DMSO, 0.02% NaN3) bu¡er was used as di-
luent throughout the experiments.
2.4. Association rate constant (kon) measurement
Association rate constant measurements were started by adding
various concentrations of N-TIMP-3 proteins (5^150 nM) to
TACE-cat or TACE-long (0.1 nM), depending on the potency of
the mutants. For TACE-cat, less than 5 nM of Ser-4Met/Lys/Arg
mutants were needed for near total inhibition in less than 2000 s.
TACE-long, comparatively, required more N-TIMP-3 for inhibition.
The time course of inhibition was monitored using a continuous £uo-
rometric assay until steady state was reached, usually after 12 000 s.
The progress curve was analyzed using the Enz¢tter program (Biosoft,
Cambridge, UK) and the equation:
P ¼ V stþ ðV 03V sÞð13e3ktÞ=k
where P=product concentration; V0 = initial velocity; Vs = steady
state velocity; k=apparent ¢rst order rate constant of equilibrium
between enzyme and TIMP complex.
kon values were calculated by linear regression of k on TIMP con-
centrations.
All kon measurements were performed at least twice to con¢rm the
reproducibility of the results.
2.5. Inhibition constant (Kappi ) measurement
In all Kappi studies, TACE-cat and TACE-long (0.2 nM) were pre-
incubated with di¡erent concentrations of N-TIMP-3 or its mutants
in a ¢nal volume of 2.5 ml. Due to the diverse potency of various
N-TIMP-3 mutants against TACE-cat and TACE-long, the concen-
trations of N-TIMP-3 proteins required di¡ered among the mutants.
TACE-cat required less inhibitors, the concentrations of some tight-
binding mutants (e.g. Ser-4Met, Ser-4Lys and Ser-4Arg) typically
ranged from 0.1 to less than 5 nM. For the less potent mutants (i.e.
all Thr-2 mutants), up to 50 nM of proteins were required. On the
contrary, substantially more inhibitors were needed for all TACE-long
assays, the concentrations of some N-TIMP-3 mutants could be as
Fig. 1. Time courses of the inhibition pro¢les (kon) of wild-type N-TIMP-3, Ser-4Met and Ser-4Lys mutants against TACE-cat and TACE-
long. Wild-type N-TIMP-3 or the Ser-4 mutants were added to 0.1 nM TACE-cat or TACE-long to a ¢nal concentration of 2.5 nM and the
turnover of QF-45 substrate monitored over a period of 15 000 s. At equilibrium, Ser-4Met completely inactivated TACE-cat, but not TACE-
long. TACE-cat enzyme in the Ser-4Lys sample was still slightly active, although the Kappi value of Ser-4Lys could not be determined accu-
rately. The time scale of the experiments varied, due to the di¡erence in potency among the mutants. Y-axis: £uorescence in arbitrary units;
X-axis: time in seconds.
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much as 150 nM. Incubation was allowed for 3 h at room temperature
prior to steady state (Vs) measurement. Measurements of enzyme
activities were initiated by adding £uorescent substrate QF-45 to a
¢nal concentration of 1 WM. The time courses were ¢tted into com-
petitive tight binding equations with the computer program Gra¢t to
obtain an estimation of Kappi values:
V s ¼ ðV0=2EtÞUfðEt3I t3Kappi Þ þ ½ðKappi þ I t3EtÞ2 þ 4Et Kappi 1=2g
where V0 = rate in the absence of inhibitor; Et = total enzyme concen-
tration; It = total inhibitor concentration.
2.6. Inhibition constant (Kappi ) with hydroxamate acids
As with N-TIMP-3 mutants in Section 2.5, similar concentrations
of TACE-cat and TACE-long were used in determining the Kappi val-
ues of hydroxamate inhibitors. Enzymes were pre-incubated with up
to 10 nM of hydroxamate acids for 3 h at room temperature before
steady state velocities (Vs) were measured.
3. Results
3.1. Kappi pro¢les of Thr-2, Ser-4 and Leu-67 mutants against
TACE-cat and TACE-long
Most Ser-4 mutants displayed extremely high binding a⁄n-
ities against TACE-cat (Kappi 6 60 pM) (Table 1 and Fig. 1).
In fact, the accurate Kappi values of Ser-4Met, Ser-4Lys and
Ser-4Arg mutants were beyond the sensitivity limit of our
£uorometric assays. As shown in Fig. 2, TACE-cat was totally
inactivated by the Ser-4Met mutant at the inhibitor:enzyme
(I:E) ratio of 5:1 when steady state was ¢nally achieved.
TACE-long, on the contrary, could not be completely inacti-
vated by the same mutant even when the I:E ratio was raised
to 20:1. The contrast between the inhibitory potency of
N-TIMP-3 mutants against the two variants of TACE is
best re£ected by the time courses of their action. Fig. 1 sum-
marizes the kon pro¢les of wild-type N-TIMP-3, Ser-4Met and
Ser-4Lys mutants against TACE-cat and TACE-long. At
equilibrium, TACE-cat and TACE-long enzymes in the
wild-type N-TIMP-3 samples still showed detectable activity
against QF-45. On the other hand, the Ser-4Met mutant was
capable of completely inactivating TACE-cat, but not TACE-
long. In any event, regardless of the mutants, TACE-long was
always more resilient to N-TIMP-3 inhibition than TACE-cat.
The Kappi pro¢les of the same mutants against TACE-cat and
TACE-long are shown in Fig. 2.
In comparison to wild-type N-TIMP-3, all Thr-2 mutants
have impaired a⁄nities against both TACE-cat and TACE-
long. Despite the general reduction in binding tightness, yet
again, all Thr-2 mutants demonstrated a similar pattern of
inhibition as their Ser-4 counterparts, i.e. their a⁄nities with
TACE-long were consistently lower than with TACE-cat (Ta-
ble 1). As a matter of fact, without exception, all wild-type as
well as mutant N-TIMP-3 exhibited nearly 10-fold lower af-
¢nity against TACE-long than TACE-cat.
3.2. Association rates (kon) of N-TIMP-3 mutants with
TACE-cat and TACE-long: increase e⁄ciency of
Thr-2Met, Ser-4Met and Ser-4Tyr
Association rate constants (kon) are the re£ection of the
swiftness of TACE and N-TIMP-3 molecules in forming a
stable binary complex. In comparison with TACE-cat, wild-
type N-TIMP-3 was nearly an order of magnitude less e⁄cient
in forming a binary complex with TACE-long (TACE-long
konV0.5U105 M31 s31 ; TACE-cat konV4U105 M31 s31);
so were most of the N-TIMP-3 mutants (Table 2). When all
the Thr-2, Ser-4 and Leu-67 mutants were aligned against
wild-type N-TIMP-3, a clear pattern emerged suggesting
that Thr-2Met, Ser-4Met and Ser-4Tyr mutants were in fact
more e⁄cient than wild-type N-TIMP-3 in associating with
TACE-long (wild-type konV0.5U105 M31 s31 ; Thr-2Met,
Ser-4Met, Ser-4Tyr konV2^5U105 M31 s31). The gain in ef-
¢ciency was no doubt the direct result of enhancing the length
and hydrophobicity of residue-2 and -4 side chains.
3.3. Inhibition constants (Kappi ) of TACE-cat and TACE-long
with hydroxamate inhibitors
Four di¡erent species of hydroxamate compounds were
chosen for this study, with the criteria for their selection based
primarily on the discrepancy in the bulkiness of their P1P and
P3P sub-units (Fig. 3). CT2256 has relatively small P1P and P3P
groups that should ¢t relatively well into the S1P and S3P
pockets of TACE-cat, although we suspect there might still
be space for expansion in the P3P sub-unit. CT1399 and
CT435, on the other hand, were chosen for their large P1P
Table 1
Kappi of wild-type N-TIMP-3, Thr-2, Ser-4 and Leu-67 mutants
against TACE-cat and TACE-long
Kappi (nM)
TACE-cata TACE-long
FL-TIMP-3 0.20X 0.03 0.74X 0.04a
N-TIMP-3a 0.22X 0.07 1.75X 0.20a
Thr-2Leu 0.49X 0.07 2.78X 0.20
Thr-2Met 0.77X 0.06 4.20X 0.10
Thr-2Tyr 1.30X 0.16 8.03X 0.03
Ser-4Met 6 0.060 1.01X 0.03
Ser-4Lys 6 0.060 0.96X 0.13
Ser-4Arg 6 0.060 0.49X 0.07
Ser-4Leu 0.066X 0.016 0.53X 0.10
Ser-4Tyr 0.063X 0.012 0.96X 0.05
Leu-67Met 0.073X 0.014 1.67X 0.33
All Ser-4 and Leu-67 mutants have higher a⁄nities against TACE-
cat in comparison with the wild-type N-TIMP-3. The Kappi values of
Ser-4Met/Lys/Arg mutants against TACE-cat could not be measured
accurately due to the tight binding nature of the inhibitors. Note
that the Kappi values of Thr-2 mutants increase with the length of
the residue. Also, all Ser-4 mutants displayed similar a⁄nities
against TACE-long. FL-TIMP-3: full-length TIMP-3.
aResults previously published [11,12].
Table 2
Association rate constants (kon) of wild-type N-TIMP-3, Thr-2,
Ser-4 and Leu-67 mutants against TACE-cat and TACE-long
kon (U105 M31 s31)
TACE-cata TACE-long
FL-TIMP-3 9.94X 0.46 0.98X 0.13a
N-TIMP-3a 3.65X 0.33 0.46X 0.14a
Thr-2Leu 1.12X 0.05 0.43X 0.07
Thr-2Met 3.34X 1.01 2.32X 0.11
Thr-2Tyr 0.48X 0.05 0.23X 0.04
Ser-4Met 3.00X 0.42 2.27X 0.69
Ser-4Lys 3.12X 0.22 0.29X 0.04
Ser-4Arg 1.84X 0.19 0.20X 0.02
Ser-4Leu 2.66X 0.04 0.47X 0.07
Ser-4Tyr 2.71X 0.02 4.47X 1.16
Leu-67Met 2.96X 1.44 0.59X 0.14
Wild-type N-TIMP-3 has lower association rate with TACE-long
than with TACE-cat. However, Thr-2Met, Ser-4Met and Ser-4Tyr
mutants show improved association rates against TACE-long in
comparison with the wild-type N-TIMP-3. FL-TIMP-3: full-length
TIMP-3.
aResults previously published [11,12].
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and/or P3P sub-units. In our opinion, if TACE-cat and TACE-
long do di¡er in their active site con¢guration, these two
compounds should be able to re£ect the divergence by yield-
ing di¡erent Kappi values with the two species of TACE. The
last compound, AG3340, belongs to the novel class of inhib-
itor without the conventional P1P and P3P sub-units. Evi-
dently, all CT2256, CT1399, AG3340 and CT435 exhibited
near identical Kappi values with both TACE-cat and TACE-
long. Thus, our results e¡ectively rule out the possibility that
TACE-cat and TACE-long have major di¡erences in their
overall active site con¢guration.
4. Discussion
In our previous report, we described the creation of a novel
generation of ‘super’ N-TIMP-3 mutants that bind to the
catalytic domain truncate of TACE with extremely tight af-
¢nity (Kappi 6 60 pM) [12]. The design of these ‘super-mutants’
was based solely on the published crystal structure of the
catalytic domain truncate of the TACE enzyme [19]. In spite
of the remarkable improvement in binding tightness in vitro,
our cell-based TNF-K shedding analysis showed that, among
others, the super-mutant Ser-4Met (Kappi 6 60 pM against
TACE-cat) was only marginally better than the wild-type
N-TIMP-3 in inhibiting native TACE activity [12]. One of
the most likely causes for such discrepancy in potency, in
our opinion, was the interference posed by the C-terminal
domains of the native TACE enzyme. Therefore, we decided
to extend our studies to TACE-long, the variant of recombi-
nant TACE that bore more resemblance to the native enzyme
as it retained the disintegrin, EGF-like and crambin-like do-
mains at its C-terminus. Here, we demonstrate that these
C-terminal domains do signi¢cantly weaken the inhibitory
activity of N-TIMP-3.
At this stage, we ruled out the likelihood that the C-termi-
nal domains have somehow altered the overall con¢guration
of the S1P and S3P pockets. TACE-cat and TACE-long
showed indistinguishable Kappi values with all the hydroxa-
mate inhibitors, indicating no extensive dissimilarity in their
active site con¢guration. Moreover, in the original paper de-
scribing the expression and puri¢cation of the enzymes by
Milla et al., TACE-cat and TACE-long were also demon-
strated to have similar kcat/Km values in synthetic peptide
turnover (kcat/Km TACE-cat 1.3U105 M31 s31 ; TACE-long
1.8U105 M31 s31) [18].
Instead, our ¢ndings point to steric hindrance being the
more likely explanation for the lower potency of N-TIMP-3
with TACE-long. In particular, the kon data of Thr-2Met, Ser-
4Met and Ser-4Tyr mutants suggest that the association rate
against TACE-long could be improved by increasing the
length and hydrophobicity of residue-4. In other words, our
results seem to hint at the presence of an ‘obstacle’ in TACE-
long that hinders N-TIMP-3 from docking snuggly onto the
surface of the enzyme. This ‘obstacle’, in our view, originates
from the physical obstruction posed by the C-terminal do-
mains upon an approaching N-TIMP-3 molecule. Besides,
our previous kinetic studies with full-length TIMP-3 also re-
vealed similar patterns of inhibition, i.e. the binding a⁄nities
and the association rate constants of full-length TIMP-3 with
TACE-long were consistently lower than those with TACE-
cat (Tables 1 and 2) [11]. Most amazingly, this ‘obstructive
e¡ect’ was also noted by the workers describing the expression
Fig. 2. Kappi inhibition pro¢les of wild-type N-TIMP-3, Ser-4Met and Ser-4Lys mutants against TACE-cat and TACE-long. The accurate values
for Ser-4Met and Ser-4Lys against TACE-cat could not be determined accurately due to total inhibition of the enzyme at higher concentrations
of inhibitors. On the contrary, TACE-long was much more resilient towards N-TIMP-3 inhibition. Y-axis: rate of QF-45 catalysis; X-axis: con-
centration of N-TIMP-3 and mutants in pM; 7 : TACE-cat; F : TACE-long.
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and puri¢cation of the TACE-cat and TACE-long enzymes.
In the paper by Milla et al., TACE-cat was observed to be
capable of forming a tight, inactive complex with the pro-
domain of TACE during protein expression. In order to re-
lease the enzyme, up to 4 M of urea was required to denature
one or both members of the complex. TACE-long, on the
contrary, was incapable of forming such a complex with the
pro-domain [18].
An interesting yet demanding challenge prompted by the
current study is the question of whether the soluble form of
TACE-long enzyme in our solution assay system genuinely
resembles native TACE that exist on the cell surface. Given
the fact that TIMP-3 appears to be a signi¢cant regulator of
TACE in vivo, it is important to recognize its role in relation
to the development of many TACE-related clinical disorders.
Currently, a number of other ADAM and ADAM-TS pro-
teinases are known to be inhibited by TIMP-1 and/or -3 [10^
12,17,20]. Many biochemical and kinetic data derived from
these ADAM proteinases could only be performed with solu-
ble or truncated forms of enzyme frequently lacking various
domains. Thus, our ¢ndings highlight the di⁄culty of relating
in vitro biochemical data to actual cellular events and the
importance of conducting the latter type of assays. Under-
standing the e¡ects of these C-terminal domains on TIMP
action would no doubt be of utmost importance in drug de-
sign and targeting in the future.
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